Streetbeat News

EXFY

Expensify, Inc.

https://www.expensify.com

Industry

Software - Application

Expensify, Inc. provides a cloud-based expense management software platform to individuals, small businesses, and corporations in the United States and internationally. The company's platform enables users to manage corporate cards, pay bills, generate invoices, collect payments, and book travel. It also offers track and submit plans for individuals. The company was founded in 2008 and is based in Portland, Oregon.

Open

3.38

Mkt cap

313M

Volume

441K

High

3.54

P/E Ratio

-28.50

52-wk high

4.13

Low

3.38

Div yield

N/A

52-wk low

1.24

Expensify (NASDAQ:EXFY) reported Q2 2024 adjusted EPS of $0.06, beating the analyst estimate of $0.04. However, sales of $33.288 million missed the $36.148 million estimate and were down 14.39% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:06 pm

JMP Securities analyst Joe Goodwin has reiterated a Market Perform rating on Expensify (NASDAQ:EXFY).

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 4:38 pm

Insiders are buying shares of Expensify, Bio Essence, and Perspective Therapeutics, indicating confidence in these companies despite recent challenges. Expensify posted downbeat quarterly results, Bio Essence's stock surged 127% in the past month, and Perspective Therapeutics announced an $80 million underwritten offering.

Portfolio Pulse from Avi Kapoor

June 04, 2024 | 11:24 am

Expensify reported Q1 2024 earnings of $0.04 per share, missing the consensus estimate of $0.05, and sales of $33.535M, missing the estimate of $35.525M. This represents a decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:55 pm

Expensify has announced the upcoming launch of Expensify Travel, a new platform aimed at enhancing travel experiences for its users. This move represents a significant expansion of Expensify's service offerings beyond its traditional expense management solutions.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:08 am

Insiders at Expensify, New Peoples Bankshares, and Tecogen have recently made significant purchases of their companies' stocks, indicating potential confidence in their respective companies' futures. Expensify and Tecogen are both expected to announce their first-quarter financial results soon, which could be a factor influencing these insider transactions.

Portfolio Pulse from Avi Kapoor

May 06, 2024 | 11:11 am

Insiders at AmBase, Expensify, and Riverview Bancorp have recently made significant stock purchases. AmBase reported a net loss for the year, while Expensify is set to announce Q1 financial results. Riverview Bancorp posted a loss for the fourth quarter. These transactions may indicate insider confidence in the companies' future prospects.

Portfolio Pulse from Avi Kapoor

May 02, 2024 | 11:46 am

Insiders are buying shares of GrafTech International, Expensify, and Retractable Technologies, indicating confidence in these companies. GrafTech reported strong Q1 results, Expensify is set to announce Q1 results, and Retractable Technologies has already reported its results for 2023.

Portfolio Pulse from Avi Kapoor

April 30, 2024 | 1:17 pm

Citigroup analyst Steven Enders maintains a Buy rating on Expensify (NASDAQ:EXFY) but lowers the price target from $5 to $4.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 4:19 pm

Insiders at BioCardia, Expensify, and Clearside Biomedical have recently made significant stock purchases, signaling confidence in their companies' prospects. BioCardia's CEO acquired shares following a narrower-than-expected quarterly loss. Expensify's major owner bought shares after reporting strong Q4 earnings. Clearside Biomedical's director made purchases after a new executive joined its board.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 11:38 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.